File Download
  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Article: Enteric coated Mycophenolate Sodium combined with low-dose steroid as first time therapy in minimal change nephrotic syndrome: an open label randomized controlled study

TitleEnteric coated Mycophenolate Sodium combined with low-dose steroid as first time therapy in minimal change nephrotic syndrome: an open label randomized controlled study
Authors
KeywordsNephropathy
Mycophenolate
Minimal change disease
Issue Date2018
PublisherImpact Journals LLC. The Journal's web site is located at http://www.impactjournals.com/oncotarget/index.html
Citation
Oncotarget, 2018, v. 2018 How to Cite?
AbstractBackground: Mycophenolate has been shown to be effective in glomerular disease. However, the role of mycophenolate in the first-line treatment of adult onset idiopathic minimal change disease (MCD) has not been systematically studied in a randomized fashion. Materials and Methods: 20 adult patients with biopsy proven MCD were recruited and randomly assigned to recevie either enteric coated Mycophenolate Sodium (EC-MPS) plus low dose prednisolone (Group 1: Prednisolone 0.25 mg/kg/day, n = 10) or standard dose prednisolone (Group 2: Prednisolone 1 mg/kg/day, n = 10). Results: After 24 weeks of therapy, 80% (n = 8) of patients in Group 1 vs 70% (n = 7) of patients in Group 2 achieved complete remission (p = 0.606). Both groups showed a significant reduction of urine protein excretion (p < 0.05) and increased serum albumin (p < 0.001) vs baseline levels. However, no significant between-group differences were demonstrated. The relapse rate was also similar in both groups (Group 1: 10% vs Group 2: 10%). EC-MPS treatment was well tolerated but 5 out of 10 patients from the standard-dose prednisolone group reported adverse reaction towards the assigned treatment. Conclusions: EC-MPS plus low dose prednisolone is non-inferior to standard-dose prednisolone therapy in inducing clinical remission and preventing relapse in adult onset idiopathic MCD and is associated with better tolerability and less adverse effects. This trial is registered with the ClinicalTrials.gov number NCT01185197.
Persistent Identifierhttp://hdl.handle.net/10722/259365
ISSN
2015 Impact Factor: 5.008
2015 SCImago Journal Rankings: 2.294

 

DC FieldValueLanguage
dc.contributor.authorMa, MK-
dc.contributor.authorYap, YHD-
dc.contributor.authorLi, CL-
dc.contributor.authorMok, MM-
dc.contributor.authorChan, GCW-
dc.contributor.authorKwan, LP-
dc.contributor.authorLai, KN-
dc.contributor.authorTang, SCW-
dc.date.accessioned2018-09-03T04:06:12Z-
dc.date.available2018-09-03T04:06:12Z-
dc.date.issued2018-
dc.identifier.citationOncotarget, 2018, v. 2018-
dc.identifier.issn1949-2553-
dc.identifier.urihttp://hdl.handle.net/10722/259365-
dc.description.abstractBackground: Mycophenolate has been shown to be effective in glomerular disease. However, the role of mycophenolate in the first-line treatment of adult onset idiopathic minimal change disease (MCD) has not been systematically studied in a randomized fashion. Materials and Methods: 20 adult patients with biopsy proven MCD were recruited and randomly assigned to recevie either enteric coated Mycophenolate Sodium (EC-MPS) plus low dose prednisolone (Group 1: Prednisolone 0.25 mg/kg/day, n = 10) or standard dose prednisolone (Group 2: Prednisolone 1 mg/kg/day, n = 10). Results: After 24 weeks of therapy, 80% (n = 8) of patients in Group 1 vs 70% (n = 7) of patients in Group 2 achieved complete remission (p = 0.606). Both groups showed a significant reduction of urine protein excretion (p < 0.05) and increased serum albumin (p < 0.001) vs baseline levels. However, no significant between-group differences were demonstrated. The relapse rate was also similar in both groups (Group 1: 10% vs Group 2: 10%). EC-MPS treatment was well tolerated but 5 out of 10 patients from the standard-dose prednisolone group reported adverse reaction towards the assigned treatment. Conclusions: EC-MPS plus low dose prednisolone is non-inferior to standard-dose prednisolone therapy in inducing clinical remission and preventing relapse in adult onset idiopathic MCD and is associated with better tolerability and less adverse effects. This trial is registered with the ClinicalTrials.gov number NCT01185197.-
dc.languageeng-
dc.publisherImpact Journals LLC. The Journal's web site is located at http://www.impactjournals.com/oncotarget/index.html-
dc.relation.ispartofOncotarget-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectNephropathy-
dc.subjectMycophenolate-
dc.subjectMinimal change disease-
dc.titleEnteric coated Mycophenolate Sodium combined with low-dose steroid as first time therapy in minimal change nephrotic syndrome: an open label randomized controlled study-
dc.typeArticle-
dc.identifier.emailYap, YHD: desmondy@hku.hk-
dc.identifier.emailLai, KN: knlai@hku.hk-
dc.identifier.emailTang, SCW: scwtang@hku.hk-
dc.identifier.authorityYap, YHD=rp01607-
dc.identifier.authorityLai, KN=rp00324-
dc.identifier.authorityTang, SCW=rp00480-
dc.description.naturepublished_or_final_version-
dc.identifier.hkuros288116-
dc.identifier.volume2018-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats